Moon-kyung Jung

Moon-kyung Jung


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MJMi-Hyang Jung
Mi-Hyang Jung
MJMoon-kyung Jung
Moon-kyung Jung
EKEui-Soon Kim
Eui-Soon Kim
JYJong-Chan Youn
Jong-Chan Youn
ELEun Young Lee
Eun Young Lee
HKHyeon Chang Kim
Hyeon Chang Kim
Background/Objectives: Cancer survivors increasingly face cardiovascular disease (CVD), with diabetes as a major risk factor. This study investigates the relationship between adherence to antidiabetic medications and cardiovascular (CV) outcomes in cancer patients. Methods: Using data from the Korean National Health Insurance Service—National Sample Cohort, we assessed the clinical outcomes of adult cancer patients prescribed antidiabetic medications. The study population was categorized based on medication adherence, as determined by the medication possession ratio (MPR): good (MPR ≥ 0.8), moderate (0.5 ≤ MPR < 0.8), and poor (MPR < 0.5) adherence. The primary outcomes included overall and CV mortality, with secondary outcomes encompassing hospitalization for major CVDs and healthcare costs. Results: Among the 7928 cancer patients with diabetes, 59.7% were nonadherent (22.1% with moderate and 37.6% with poor adherence). Over a median follow-up of 5.7 years, 1462 deaths and 2897 CV events were confirmed. Multivariable adjusted analyses showed a 1.70-fold and 2.11-fold higher risk of overall mortality for the moderate and poor adherence groups, respectively, compared to the good adherence group. For CV mortality, moderate adherence was associated with a 1.51-fold higher risk, and poor adherence with a 2.10-fold higher risk. The risk for new-onset CV events increased by 1.32-fold in the moderate adherence group and 1.44-fold in the poor adherence group. The good adherence group also showed significantly lower total healthcare costs compared to the nonadherence group. Conclusions: The present study underscores the importance of adherence to antidiabetic medications in cancer patients, revealing significant associations with decreased mortality, CV events, and healthcare costs.

2 July 2024 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
MJMoon-kyung Jung
Moon-kyung Jung
HKHwan Wook Kim
Hwan Wook Kim
KBKyongmin Sarah Beck
Kyongmin Sarah Beck
YSYeoun Eun Sung
Yeoun Eun Sung
MJMi-Hyang Jung
Mi-Hyang Jung
Background: Pulmonary thromboembolism and active haemoptysis represent distinct yet critical emergencies necessitating immediate intervention. However, the treatment protocols for these conditions—anticoagulation therapy and haemostatic therapy—often pose a dilemma. Case summary: We present the case of a 25-year-old female who presented to our emergency room with haemoptysis and a concurrent diagnosis of pulmonary thromboembolism. Due to persistent active haemoptysis, we temporarily paused anticoagulation and opted for surgical pulmonary thrombectomy, enabling the safe resumption of anticoagulation therapy. Discussion: Haemoptysis occurring in pulmonary thromboembolism is infrequently reported in the literature, and established treatment guidelines for such cases are lacking. This case could provide guidance on how to handle the intricate treatment challenges posed by concurrent haemoptysis and pulmonary thromboembolism.

1 January 2023 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
OKOh Beom Kwon
Oh Beom Kwon
MJMoon-kyung Jung
Moon-kyung Jung
HJHyonsoo Joo
Hyonsoo Joo
Kwon OB, et al. J Korean Med Sci. 2023 Jan;38(6):e45. https://doi.org/10.3346/jkms.2023.38.e45

1 December 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
KKKyung An Kim
Kyung An Kim
MJMoon-kyung Jung
Moon-kyung Jung
EKEui-Soon Kim
Eui-Soon Kim
DKDongwoo Kim
Dongwoo Kim
JKJoon-Seok Kim
Joon-Seok Kim
JYJong-Chan Youn
Jong-Chan Youn
Background: Familial hypercholesterolemia (FH) continues to be underrecognized and inadequately treated. We aimed to investigate the current status of FH diagnosis and treatment in South Korea. Methods: Patients from two tertiary hospitals in South Korea between 2010 and 2023 with either a diagnosis of FH (ICD-10 code: E7800), had LDLR, APOB, or PCSK9 mutations, or had low-density lipoprotein cholesterol (LDL-C) levels exceeding 325 mg/dL were considered for inclusion. Demographic and laboratory characteristics as well as pharmacologic treatment patterns were assessed. Results: A total of 148 patients were retrospectively identified. The mean age at diagnosis was 49.3 years, and 33 (22.3%) had a history of established atherosclerotic cardiovascular disease (ASCVD). The majority of patients were diagnosed in the cardiology or endocrinology departments. The LDL-C level at enrollment was 247 ± 98 mg/dL (conversion to treatment-naïve LDL-C: 343 ± 141 mg/dL), which decreased to 122 ± 60 mg/dL after one year, achieving guideline-recommended target levels in 11.5%. A high proportion of patients were treated with statins (80.2%) and ezetimibe (64.9%), but the use of proprotein convertase subtilisin/kexin type 9 inhibitors was low (11.7%). Patients diagnosed after 2020 achieved significantly lower LDL-C levels at one year compared to those diagnosed between 2020 and 2019 (107 ± 50 vs. 152 ± 68 mg/dL, p = 0.003). Two ischemic strokes and two myocardial infarctions occurred during a median follow-up of 25.3 months. Conclusions: FH is frequently diagnosed late after the onset of clinical ASCVD and is undertreated, although recent trends show improvement. Our results again underline the need for proper screening and identification of patients with FH.